The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies

Small molecule inhibitors have previously been investigated in different studies as possible therapeutics in the treatment of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In the current drug repurposing study, we identified the leukotriene (D4) receptor antagonist montelukast as a n...

Descripción completa

Detalles Bibliográficos
Autores principales: Durdagi, Serdar, Avsar, Timucin, Orhan, Muge Didem, Serhatli, Muge, Balcioglu, Bertan Koray, Ozturk, Hasan Umit, Kayabolen, Alisan, Cetin, Yuksel, Aydinlik, Seyma, Bagci-Onder, Tugba, Tekin, Saban, Demirci, Hasan, Guzel, Mustafa, Akdemir, Atilla, Calis, Seyma, Oktay, Lalehan, Tolu, Ilayda, Butun, Yasar Enes, Erdemoglu, Ece, Olkan, Alpsu, Tokay, Nurettin, Işık, Şeyma, Ozcan, Aysenur, Acar, Elif, Buyukkilic, Sehriban, Yumak, Yesim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524809/
https://www.ncbi.nlm.nih.gov/pubmed/34678509
http://dx.doi.org/10.1016/j.ymthe.2021.10.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524809/
https://www.ncbi.nlm.nih.gov/pubmed/34678509
http://dx.doi.org/10.1016/j.ymthe.2021.10.014

Ejemplares similares